Reveal® XT Performance Trial (XPECT)

PHASE4CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Atrial FibrillationRisk of Cardiac Arrhythmias
Interventions
OTHER

46 hrs Holter ECG recording

Maximum of 2 46 hrs external Holter ECG recordings are required.

Trial Locations (24)

4010

A.ö. Krankenhaus der Elisabethinen Linz, Linz

197341

Almazov Federal Heart, Blood & Endocrinolgoy Centre, Saint Petersburg

630055

Scientific Research Institute of Circulation Pathology, Novosibirsk

A-6020

LKH - Universitätskliniken, Innsbruck

A-5020

Salzburger Landeskliniken, Salzburg

B-3000

University Gasthuisberg, Leuven

G1V 4G5

Hopital Laval, Québec

V6Z 1Y6

St. Paul's Hospital, Vancouver

V8R 4R2

Victoria Cardiac Arrhythmia Trials Inc., Victoria

CZ-625 00

Facultni Nemocnice Brno, Brno

150 30

Nemocnice Na Homolce Hospital, Prague

CZ 140-21

Klinika Kardiologie IKEM, Prague

D-79189

Herzzentrum Bad Krozingen, Elektrophysiologie, Bad Krozingen

D-61231

Kerckhoff Klinik Forschungsgesellschaft, Bad Nauheim

D-10117

Charité Campus Mitte, Berlin

D-53105

Universitätsklinikum Bonn, Bonn

D-20099

Asklepios Klinik St. Georg, Hamburg

Unknown

Universität Leipzig Herzzentrum, Leipzig

UMC Maastricht, Maastricht

D-72076

Medizinische Universitätsklinik Tübingen, Tübingen

1815 JD

Medisch Centrum Alkmaar, Alkmaar

2353 GA

Rijnland Ziekenhuis, Leiderdorp

974 01

SsUSCH Baska Bystrica, Banská Bystrica

833 48

NUSCH Bratislava a.s., Bratislava

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Medtronic BRC

INDUSTRY

NCT00680927 - Reveal® XT Performance Trial (XPECT) | Biotech Hunter | Biotech Hunter